Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
Benefits outweigh risks when switching biologics for rheumatoid arthritis
Patients with rheumatoid arthritis who achieve only a partial response with adalimumab demonstrate a low risk for worsened symptoms and a high likelihood of meaningful improvement when switching to sarilumab, according to data.
‘Definitely not expecting this’: Bacteria from ‘leaky gums’ may trigger RA flares
Patients with rheumatoid arthritis and periodontal disease may experience flares due to bacteria from “leaky gums” moving into their bloodstream and causing inflammation, according to recent findings.
Log in or Sign up for Free to view tailored content for your specialty!
Olokizumab effective in patients with rheumatoid arthritis unresponsive to TNF inhibitors
In patients with rheumatoid arthritis who failed to respond to TNF inhibitors, olokizumab is effective and carries an acceptable safety risk, especially when paired with methotrexate, according to data published in Clinical Rheumatology.
FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz
The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.
‘A good start’: ACR guideline heralds increased use, recognition of integrative therapies
Integrative medicine approaches such as tai chi and yoga, which have long been used in rheumatology in a secondary or supplementary role, are increasingly being viewed as essential care.
EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis
Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.
Mandatory switching policies increased etanercept, infliximab biosimilar use in Canada
Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.
Long-term sarilumab demonstrates no new safety concerns in rheumatoid arthritis
Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.
Rheumatoid arthritis may be strong driver for incident HF
Rheumatoid arthritis is independently associated with incident HF across the range of ejection fraction, with a stronger association among those with an EF of at least 40%, researchers reported.
Older patients with rheumatic disease report low levels of ‘vigorous’ physical activity
Older patients with rheumatic diseases are less to report “vigorous” levels of physical activity, compared with other age groups, which may lead to more lifestyle difficulties, according to data published in The Journal of Rheumatology.
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read